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ABSTRACT
Indoleamine 2,3-deoxygenase 1 (IDO1) induces immune tolerance in the tumor microenvironment (TME) and is
recognized as a potential therapeutic target. We studied the expression of both IDO1 and the related tryptophan
2,3-dioxygenase (TDO) in several different subtypes of cutaneous T-cell lymphoma (CTCL), and evaluated the
kynurenine (KYN) pathway in the local TME and in patient sera. Specimens from the total of 90 CTCL patients,
including mycosis fungoides (MF, nD 37), lymphomatoid papulosis (LyP, nD 36), primary cutaneous anaplastic
large cell lymphoma (pcALCL, n D 4), subcutaneous panniculitis-like T-cell lymphoma (SPTCL n D 13), and 10
patients with inﬂammatory lichen ruber planus (LRP), were analyzed by immunohistochemistry (IHC),
immunoﬂuorescence (IF), quantitative PCR, and/or liquid chromatography–tandem mass spectrometry (LC–MS/
MS). Three CTCL cell lines also were studied. Expression of both IDO1 and TDO was upregulated in CTCL. In MF
specimens and in the MF cell line MyLa2000, IDO1 expression exceeded that of TDO, whereas the opposite was
true for LyP, ALCL, and corresponding Mac1/2A cell lines. The spectrum of IDO1-expressing cell types differed
among CTCL subtypes and was reﬂected in the clinical behavior. In MF, SPTCL, and LyP, IDO1 was expressed by
malignant cells and by CD33C myeloid-derived suppressor cells, whereas in SPTCL CD163C tumor-associated
macrophages also expressed IDO1. Signiﬁcantly elevated serum KYN/Trp ratios were found in patients with
advanced stages of MF. Epacadostat, an IDO1 inhibitor, induced a clear decrease in KYN concentration in cell
culture. These results show the importance of IDO1/TDO-induced immunosuppression in CTCL and emphasize
its role as a new therapeutic target.
Abbreviations: APC, antigen presenting cell; CTCL, cutaneous T-cell lymphoma; CTLA-4, cytotoxic T-lymphocyte
associated protein 4; DC, dendritic cell; IDO1, indoleamine-2,3-dioxygenase 1; KYN, kynurenine; LRP, lichen ruber
planus; LyP, lymphomatoid papulosis; MF, mycosis fungoides; MDSC, myeloid-derived suppressor cell; pcALCL, pri-
mary cutaneous anaplastic large cell lymphoma; PD, programmed cell death; SPTCL, subcutaneouos panniculitis-like
T cell lymphoma; Trp, tryptophan; TDO, tryptophan-2,3-dioxygenase; TAM, tumor-associated macrophage; TME,
tumor microenvironment
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Introduction
Prognostic and therapeutic implications of tissue and serum
levels of indoleamine 2,3-dioxygenase 1 (IDO1 also known as
IDO), tryptophan (Trp), and kynurenine (KYN) are currently
of great interest in cancer research. IDO1-catalyzed depletion
of Trp in the tumor microenvironment (TME) results in release
of soluble KYN and downstream metabolites, renders regula-
tory T cells (Tregs) and antigen presenting cells (APCs) tolero-
genic, and inhibits antitumor T cell responses.1 Three enzymes,
namely IDO1, tryptophan 2,3-dioxygenase (TDO, also known
as TDO2), and indoleamine 2,3-dioxygenase 2 (IDO2), catabo-
lize the same rate-limiting step in the conversion of Trp into
KYN.2 IDO1 and TDO share limited structural homology but
have distinct enzymatic properties and differ in their expression
proﬁle in normal and neoplastic tissues.3 Constitutive expres-
sion of IDO1 occurs in the placenta, eye, pancreas, eosinophils,
and certain dendritic cell (DC) subsets. Many malignant cells,
tumor-associated cells including myeloid-derived suppressor
cells (MDSCs) and macrophages (TAMs) express IDO1 and its
upregulation has been reported in human neoplasms,4,5 includ-
ing Hodgkin6 systemic anaplastic large cell lymphoma,7 and
adult T-cell leukemia/lymphoma (ATLL).8
IDO1 expression is actively induced by inﬂammation and T cell
activation. Interestingly, as a counter-regulatory action, IDO1 fur-
ther acts to suppress these same signals. This is advantageous when
CONTACT Pilvi Maliniemi, PhD cloudnro9@hotmail.com Department of Dermatology and Allergology, Inﬂammation Center, Helsinki University Central Hospi-
tal, Haartmaninkatu 8, 00250 Helsinki, Finland.
Supplemental data for this article can be accessed on the publisher’s website.
Published with license by Taylor & Francis Group, LLC © Pilvi Maliniemia, Kirsi Laukkanen, Liisa V€akev€a, Katja Dettmerb, Tuomas Lipsanena, Leila Jeskanena, Alban Bessedec, Peter J. Oefnerb,
Marshall E. Kadind, and Annamari Ranki.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unre-
stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
ONCOIMMUNOLOGY
2017, VOL. 6, NO. 3, e1273310 (10 pages)
http://dx.doi.org/10.1080/2162402X.2016.1273310
IDO1 is controlling harmful inﬂammation but unfavorable if sup-
pressing antitumor responses.1 IDO1 also plays an important role
in peripheral tolerance required to suppress autoimmunity. In
these conditions, IDO1 is expressed mostly by APCs, such as DCs
and macrophages, in response to signals like interferon-gamma
(IFNg) or activation of signal transducer and activator of transcrip-
tion 3 (STAT3).9 Overall, IDO1 can regulate inﬂammatory
responses and change the local milieu from immunogenic to tol-
erogenic.10,9,1 Strong TDO expression has been observed mainly in
hepatocellular carcinoma.3,11 The nature of TDO-expressing cells
in tumors is poorly characterized and even less is known about
IDO2.12,13,14,15 We reported that IDO1 is among the most highly
upregulated genes in subcutaneous panniculitis-like T-cell lym-
phoma (SPTCL),16 which is a rare form of CTCL with a favorable
prognosis and good response to immunosuppressive therapy.17,18
The same study showed upregulation of CTLA-4 and PD-L1 in
SPTCL.16 These checkpointmolecules are among themost promis-
ing therapeutic targets for cancer immunotherapy. In ongoing clin-
ical trials for multiple solid tumor patients, CTLA-4 and PD-1/PD-
L1- targeting antibodies are combined with IDO1 inhibitors.1,19
Since the TME and, in particular, tumor-inﬁltrating macro-
phages and DCs are believed to be involved in tumor progres-
sion and treatment resistance (reviewed in ref. 20), we
undertook this study to clarify the cell-speciﬁc expression of
IDO1 in additional types of CTCL, including lymphomatoid
papulosis (LyP), primary cutaneous anaplastic large cell lym-
phoma (pcALCL), and mycosis fungoides (MF). LyP and
pcALCL share a CD30C immunophenotype and favorable
prognosis. LyP is a chronic papulonecrotic or papulonodular
skin disease with histology suggestive of malignant lymphoma
but with spontaneous regression.21 Spontaneous regressions of
skin tumors are less frequent in pcALCL. LyP and MF may
share a similar clonal T cell origin.22 The risk of a secondary
lymphoma is high in LyP patients, with 10–40% developing
other lymphomas.23 We compared the expression of IDO1,
TDO, and KYN in the CD30C lymphoproliferative Mac1/2A
cell lines24 and the MF-derived cell line MyLa2000.25 To further
understand the systemic immunosuppressive effects, we ana-
lyzed serum levels of Trp, KYN, and other intermediates of the
KYN pathway in MF and LyP patients.
Results
Converse expression patterns of IDO1 and TDO in CTCL
subgroups
In MF, the relative mRNA expression level of IDO1 was increased
3- to 4-fold compared with the expression of TDO (Fig. 1A).
Interestingly, in LyP and ALCL the opposite was true; with TDO
mRNA expression exceeded that of IDO1 by approximately 10-
fold. A concordant disparate expression proﬁle was found in rep-
resentative cell lines, too. Accordingly, IDO1 expression in the
MF-derived MyLa2000 cell line was almost 10-fold higher than
that of TDO and vice versa in Mac2A representing ALCL
(Fig. 1B). Similar conversed expression patterns were observed
using western blotting analysis (Fig. 1C). MyLa2000 was chosen
as calibrator (relative density value 1) and after normalization
against the density values of b-actin, the adjusted density values
for IDO1 in Mac1 andMac2A cells were 0.48 and 0.4, respectively.
Likewise, the corresponding density values for TDO were 1.43 and
1.45, respectively. Thus, IDO1 is 0.5-fold downregulated and
TDO2 is approximately 1.4-fold upregulated in Mac1 and Mac2A
cell lines compared with Myla2000.
Immunohistochemical (IHC) analysis of formalin-ﬁxed par-
afﬁn-embedded (FFPE) sections revealed protein expression of
IDO1 and TDO to be substantially expressed in all studied
CTCL subgroups (Fig. 2). Inﬂammatory or non-malignant cells
accounted mostly for IDO1 expression (Fig. 3A–C). In MF,
approximately 10% of morphologically malignant lymphocytes
expressed IDO1, whereas IDO1-positive macrophages often
surrounded the malignant cells (Fig. 3B). Interestingly, TDO
expression dominated especially in LyP and ALCL (Fig. 2B).
TDO was expressed by most of the large atypical cells in the
inﬂammatory inﬁltrate in LyP (Fig. 3D) as well as in malignant
lymphocytes in Pautrier microabscesses of MF (Fig. 2E). In
SPCTL, TDO was also expressed by the malignant cells sur-
rounding the adipocytes (Fig. 3F).
Since IDO1 and TDO catabolize conversion of Trp to KYN,
we also examined KYN abundance in IDO1-expressing skin
specimens. Ten of twelve IDO1-expressing LyP and all IDO1-
expressing MF samples showed sparse or moderate nuclear and/
or cytosolic KYN (Fig. 3G–H). Malignant cells also contained
KYN in MF, (Fig. 3H) and KYN was detected in morphologi-
cally malignant cells surrounding adipocytes in SPTCL (Fig. 3I).
IDO1 is expressed by different cell populations in CTCL
subgroups
We next identiﬁed IDO1-expressing cells in the lymphoma micro-
environment by performing double IHC and IF staining. Both
techniques revealed that the cell types expressing IDO1 in the
microenvironment differed between LyP, MF, and SPTCL. LyP
and MF contained considerable numbers of CD163C TAMs, but
they did not express IDO1 (Figs. 4A–D, respectively). In SPTCL,
CD163C TAMs surrounding the subcutaneous malignant lympho-
cyte inﬁltrates expressed IDO1 (Fig. 4E–F). Also, a proportion of
the morphologically malignant lymphocytes in SPTCL (Fig. 4E
and ref. 16) and inMF expressed IDO1 (ca. 10%, Fig. 4D).
Furthermore, we found CD33C myeloid derived suppressor
cells (MDSCs) to express IDO1 in all studied CTCL subtypes
(Fig. 5A). In the inﬂammatory inﬁltrates of some LyP samples,
up to 30% of the cells were IDO1C MDSCs (Fig. 5A, upper
panel), clearly exceeding the number of double-positive cells in
MF (Fig. 5A, middle panel). Interestingly, in some MF speci-
mens the IDO1-expressing cells were CD33-negative. This indi-
cates the presence of yet another IDO1-expressing cell
population in MF awaiting identiﬁcation. Double and single
positive cells for IDO1 and CD33 were found to occur fre-
quently in SPTCL (Fig. 5A, lower panel). In LyP, IDO1 was
expressed only by a limited number of CD30C cells (red)
(Fig. 5B), whereas other cell types in the TME accounted
mostly for IDO1 expression (green) (Fig. 5C).
Increased enzymatic activity of IDO1 associates with
advanced MF stage
The concentration ratio of KYN to Trp has been used widely as
an indicator of IDO1 enzymatic activity. Here, we evaluated its
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correlation to MF disease stage. First, we investigated the neces-
sity of overnight fasting and collected two partly overlapping
sets of patient sera, fasting and non-fasting. We did not detect
any signiﬁcant effect of fasting on the KYN/Trp ratio (data not
shown) and, hence, all sera were included in the ﬁnal analysis.
Overall, compared with healthy sera, the concentration of Trp
was decreased in both, LyP and MF (Figs. 6C, S2A and B).
However, only in MF the serum KYN/Trp ratio was increased
signiﬁcantly (p D 0.012, (Table 1), while it did not differ in LyP
(Fig. 6A). Elevated KYN/Trp ratios were found more often in
advanced than early stages of MF (Table 1). Correspondingly, a
moderate elevation of KYN was also found in MyLa2000 com-
pared with Mac1 and ¡2A cells (Fig. 6B).
We also measured the concentrations of 10 other KYN
pathway metabolites (Figs. 6C and S2). In a comparison of
MF to healthy sera, we found KYN and quinolinic acid
(QA) to be signiﬁcantly increased in addition to indole-3-
lactic and indole-3 acetic acids (Fig. 6C). In LyP, the levels
of the metabolites were generally lower or showed no signif-
icant difference compared with healthy sera (Fig. S2A and
B). The difference between LyP and MF was obvious as 8
of 12 KYN pathway metabolites were signiﬁcantly increased
in MF compared with LyP (Fig. S2C). Interestingly, the end
product of the KYN pathway, nicotinamide (NAm), was
signiﬁcantly decreased in both entities (Figs. 6C and S2B).
In vitro inhibition of IDO1 in MF-derived cell line
Although IDO1 inhibitors, currently in clinical trials, are not
intended to kill tumor cells directly, we studied the effect of the
IDO1 inhibitor epacadostat (INCB024360) on the IDO1-
expressing MF-derived MyLa2000 cell line. HeLa cells were
used as control cell line. IDO1 inhibition decreased the concen-
tration of KYN in the cell supernatant of MyLa2000 and HeLa
Figure 1. Gene expression of IDO1 and TDO in CTCL skin specimens and cell lines. Relative mRNA levels in (A) FFPE skin specimens of LRP, LyP, ALCL, MF, and in (B) the
cell lines Mac1 (LyP-derived), Mac2A (LyP-derived), and MyLa2000 (MF-derived). mRNA expression levels are presented as mean C/¡ SD. (C) Western blot analysis of
CTCL cell lines. A densitometer was used to evaluate the protein expressions and the adjusted density values for IDO1 and TDO fragments were calculated. MyLa2000
was chosen as calibrator (relative density value 1) and after normalization against b-actin, the adjusted density values for IDO1 in Mac1 and Mac2A cells were 0.48 and
0.4, respectively. Likewise, the corresponding density values for TDO were 1.43 and 1.45, respectively.
ONCOIMMUNOLOGY e1273310-3
cells by 29% and 53%, respectively, but had no direct effect on
cell viability, as expected (Fig. S3B and C).
Discussion
Overcoming immune tolerance in tumors has become a major
objective of cancer research and treatment. IDO1 and its
metabolite KYN have been recognized as major mediators of
immunosuppression1 and, thus, potential therapeutic targets.
Our study focused primarily on the identiﬁcation of IDO1-
expressing cells in different CTCL subtypes. We report, for the
ﬁrst time, that several cell types other than malignant cells con-
tribute to the expression of IDO1 in CTCL. Among hemato-
logic malignancies, IDO1 expression has been previously found
in the acute myeloid leukemia (AML) blasts26 and in MDSCs
in chronic lymphocytic leukemia (CLL) of B-cell origin.10 We
found the spectrum of IDO1-expressing cells to differ markedly
among CTCL subtypes. In LyP, IDO1 was prominent and
expressed by both CD33C MDSCs and CD30C large atypical
cells. While non-malignant cells in the TME, including CD33C
MDSCs, accounted for most of the IDO1 expression observed
in clinical samples of MF, about 10% of morphologically malig-
nant MF cells also expressed IDO1. Moreover, we found clus-
ters of malignant MF cells to be surrounded by IDO1-
expressing APCs or macrophages, which support the hypothe-
sis of a tumor-promoting microenvironment. In SPTCL, IDO1
expression was observed in malignant cells as well as in CD33C
MDSCs and CD163C TAMs. Recently, in lymphoma and leu-
kemia, CD163C TAMs were shown to be tumor promoting and
associated with disease progression.20
Figure 2. Relative frequencies of IDO1 and TDO expression in LRP and in each CTCL subgroup. The shade code indicates the percentage of the mononuclear cells express-
ing the given marker;C10–25% (light gray),CC 26–50% (gray), and CCC>50% (dark gray).
Figure 3. Expression of IDO1, TDO, and KYN in tissue specimens of CTCL as determined by immunohistochemistry. (A) Expression of IDO1 in LyP. (B) Expression of IDO1 in
TME of MF specimen and in macrophages surrounding the malignant cells (enlarged insert, upper right corner). (C) IDO-positive cells surrounding the adipocytes in SPTCL,
(D) Expression of TDO in LyP. (E) Expression of TDO in MF. (F) Expression of TDO in SPTCL (G) Expression of KYN in LyP. (H) Expression of KYN in MF. (I) Expression of KYN in
SPTCL. (Scale bar 20 mm and 40x magniﬁcation).
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It was somewhat unexpected, that both Mac1 and Mac2A,
clonally derived from LyP, showed only slight IDO1 mRNA
expression compared with clinical LyP specimens. This would
suggest that in vivo MDSCs cells account for most IDO1
expression in LyP. Our ﬁndings on these cell lines agree with
gene expression proﬁling data27 (see Table S3 of ref. 26 for
more details), where IDO1 was not ranked among the top 400
differentially expressed genes. Instead, Mac cells showed upre-
gulation of TDO, whose overexpression could be conﬁrmed at
mRNA and protein levels in clinical LyP and ALCL specimens
and in the CTCL cell lines (Fig. 1). Compared to IDO1, TDO
has a lower afﬁnity to L-tryptophan. Thus, it is less capable of
depleting tryptophan and causing in vitro T-cell inhibition or
activation of a stress response in Treg cells,28 which are abun-
dant in LyP tissue.29 This led to the hypothesis that anti-inﬂam-
matory and tumor-protective effects of TDO are mediated by
the production of Trp catabolites rather than by tryptophan
depletion. Interestingly, our data showed that TDO expression
exceeded that of IDO1 in LyP and ALCL. These results warrant
further study on the role of TDO in these CTCL subtypes.
In hematologic and lymphoid malignancies, high IDO1
expression was shown to associate with inferior survival and
adverse clinical outcome.6,26 Because our observation on local
KYN abundance correlated with IDO1 expression, we ran-
domly selected a cohort of LyP and MF patients under follow-
up or treatment, measured the serum concentrations of Trp
and various KYN pathway metabolites and used the KYN/Trp
ratio as an indicator of IDO1 enzymatic activity. KYN/Trp ratio
was signiﬁcantly increased in sera of MF patients compared
with healthy controls and associated with advanced disease.
Hence, the serum KYN/Trp ratio may serve as a potential prog-
nostic biomarker for progressive MF but this will require vali-
dation in a large-scale prospective study. Despite the relatively
strong local immunosuppression suspected from IDO1 expres-
sion and KYN in LyP, we did not ﬁnd any signiﬁcant difference
in the corresponding patients’ serum KYN/Trp ratios com-
pared with healthy controls (Fig. 6A). While these results sup-
port the indolent nature of LyP, it will be interesting to
determine in a prospective study whether LyP patients with ele-
vated KYN/Trp ratios suffer more frequently from second
lymphomas.
KYN and other Trp metabolites inhibit T-cell responses
mainly by their binding to the aryl hydrocarbon receptor
(AhR).30 The nuclear expression observed here may, therefore,
also indicate activated AhR receptor signaling31 also found in
Mac cell lines (MEK, article in preparation). Lastly, we wanted
Figure 4. IDO1 is expressed in CD163C TAMs in SPTCL but not in MF or LyP skin lesions. Double IHC staining for IDO1 (turquoise) and CD163 (red) showing (A and B) LyP
lesions and (C and D) MF lesions with separate cells expressing either IDO1 or CD163 (10x, and 40x, respectively), (E and F) Double positive IDO1C/CD163C TAMs are seen
surrounding the periadipocytic SPTCL inﬁltrate like a protective wall (10x and 40x, respectively). Light hematoxylin counterstaining. (Scale bar 20 mm). TAM, tumor-associ-
ated macrophage.
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to see whether we could downregulate IDO1 activity in MF-
derived cell line MyLa2000 using KYN concentration and cell
viability as parameters. It is understood that IDO1 inhibitors
are not expected to kill tumor cells directly but we were able to
demonstrate a clear decrease in the KYN concentration in these
malignant cells with epacadostat (Fig. S3B), currently under
investigation in several clinical trials (reviewed in ref 1). More-
over, IDO1-induced Treg activity, also observed here (Fig. S1),
is strictly dependent on the PD-1/PD-L1 ligand pathway to cre-
ate suppression.1 Thus, this would indicate that a combination
trial with an IDO1 inhibitor and anti-PD-1 or PD-1L might be
feasible for MF.
In summary, we show that both IDO1 and TDO are expressed
in CTCL tissues and cell lines. CTCL subtypes show unique pat-
terns of IDO1 and TDO expressions by malignant cells and cells in
the TME. Serum KYN/Trp ratios are elevated in MF patients and
correlate signiﬁcantly with advanced disease, thus being a potential
test for clinical use. We conclude that our data shows evidence of
IDO1-induced immunosuppression in CTCL and suggests that
blocking IDO1 activity might improve therapeutic responses in
CTCL in combination with other therapies.
Materials and methods
Patients and specimens
With the approval of the Medical Ethical Review Board of the Hel-
sinki and Uusimaa Hospital District, Finland and in accordance
with the Helsinki Declaration of 1975, a total of 100 patients were
enrolled, including 90 CTCLs (37 MF, 36 LyP, 4 ALCL, and 13
SPTCL), and 10 inﬂammatory LRP. All LyP specimens were sub-
type A. Diagnoses were conﬁrmed at the Dermatopathology Unit
of the Department of Dermatology and Allergology, Helsinki Uni-
versity Central Hospital (HUCH). The numbers of patients and
specimens included in the investigations performed varied and are
given in the respective sections.
For the analysis of tryptophan metabolites, serum specimens
were collected from 40 CTCL patients (14 LyP, 26 MF) fol-
lowed at HUCH and 21 healthy volunteers. Sera were collected
either after overnight fasting (14 LyP, 12 MF, and 11 healthy)
or from non-fasting individuals (22 MF, 10 healthy). Eight MF
patients donated both types of sera. The demographic features
and follow-up data of these patients are shown in Table S1. The
mean age of LyP and MF patients was 54.9 and 70.5 years,
respectively. The corresponding mean follow-up times, calcu-
lated from the time of ﬁrst histopathologically conﬁrmed diag-
nosis until the time of serum collection, were 102 and 89 mo,
respectively. Three MF patients died during follow-up, two of
MF and a third of secondary diffuse large B-cell lymphoma.
Relative gene expression
RNA was extracted from archival FFPE skin specimens avail-
able from the patients enrolled, including 10 specimens from
MF (nine patients), eight from LyP, and ﬁve from pcALCL (fol-
low-up specimens of two patients) and LRP, using NucleoSpin
FFPE RNA XS kit (cat#740969.10 Macherey-Nagel GmbH &
Co.KG) or from cell cultures with the RNeasy Mini Kit
Figure 5. CD33C/IDO1C expressing MDSCs are found in CTCL. (A) Double immunoﬂuorescence staining of CD33 (red) and IDO1 (green) in typical LyP, MF, and SPTCL
specimens. The top panel row shows a LyP tissue section with many strong double positive IDO1C/CD33C cells (yellow) and some single positive IDO1C or CD33C cells.
The second panel row shows an MF tissue section with cells either positive for IDO1C or CD33C as well as a few double positive IDO1C/CD33C cells at lower right. The
third panel row from top shows a SPTCL with double positive IDO1C/CD33C cells as well as single positive cells (40x). In addition, IDO1 is expressed by both (B) CD30-pos-
itive and (C) CD30-negative cells in LyP (40x magniﬁcation). (Scale bar 20 mm).
e1273310-6 P. MALINIEMI ET AL.
(cat#74104, Qiagen) according to manufacturers’ instructions.
No microdissection was used. From each sample, 200 ng of
RNA were subjected to reverse transcription using the Super-
Script VILO cDNA synthesis kit (cat#11754–050, Invitrogen).
The expression of IDO1 and TDO was measured by quanti-
tative PCR on a LightCycler 1.5 System (Roche Applied Sci-
ence, Germany) using 11.25 ng of cDNA per reaction, iQ
Supermix (cat#170–8860, Bio-Rad Laboratories, Inc.), and the
following TaqMan assays (IDO1; Hs00984148_m1, 66 bp,
TDO; Hs00194611_m1, cat#4448892, Life Technologies).
The relative expression levels were calculated by means of the
2¡DDCt-method using the housekeeping gene GAPDH as the
reference (TaqMan assay cat#4310884E, 118bp, Life Technolo-
gies). Samples were analyzed in triplicate, a calibrator sample
and negative controls were used. The LRP sample with the larg-
est DCt-value served as tissue reference.
Immunohistochemistry
IHC detection of the proteins IDO1 (cat#MAB5412, 1:100,
Chemicon International Inc.) and FoxP3 (cat#M3972, 1:50,
Spring Bioscience Corp.) was performed on 72 FFPE tissue
specimens: 9 LRP, 32 LyP (from 27 patients), 7 pcALCL (from 3
patients), 15 MF, and 9 SPTCL. IHC for TDO (TDO2 ab,
cat#LS-B5791, 1:200, Life Span Biosciences) was performed on 9
LRP, 30 LyP, 14 MF, 7 ALCL, and 13 SPTCL samples. Imm-
PRESS Universal Antibody (anti-mouse Ig/anti-rabbit Ig, peroxi-
dase) Polymer Detection Kit (cat#MP-7500, Vector Laboratories)
Figure 6. The activation of the KYN pathway in CTCL. (A) Signiﬁcant difference in KYN/Trp ratio between healthy controls and MF sera (pD 0.012), but no statistically sig-
niﬁcant difference between controls and LyP or between LyP and MF sera (Kruskal–Wallis test). (B) KYN concentrations in supernatants of CD30C cell lines Mac1
(1.351 mM), Mac2A (1.282 mM), and the MF-derived cell line MyLa2000 (1.650 mM) after 24 h culturing (5000 cells/96-well in 200 mL). (C) A diagram illustrating the signif-
icant changes in the concentrations of KYN pathway metabolites in MF compared with healthy sera. Red box indicates that the value is signiﬁcantly decreased; green is
signiﬁcantly increased and orange means no change (Kruskal–Wallis test).
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and NovaRED (cat#SK-4805, Vector Laboratories), DAB Peroxi-
dase Substrate Kit (cat#SK-4100, Vector Laboratories), or AEC
(cat#ab64252, Abcam) were used as chromogens. IHC for L-
KYN was performed on 7 LyP, 12 MF, and 4 SPTL specimens
with a monoclonal antibody (1:100, clone 3D4-F2, mAb,
cat#IS003, ImmuSmol) after antigen retrieval in 10 mM Tris–
HCl, pH 8.5, 1 mM EDTA, 0.05% Tween20, and using the above
ImmPRESS kit and NovaRED chromogen. Colon carcinoma
specimens were used as positive tissue controls. The IHC stain-
ing was graded as follows: indicates <10%, C10–25%, CC26–
50%, and CCC over 50% of mononuclear cells expressing a
given marker (Fig. 2A). For IHC double staining, used to identify
IDO1-expressing cells, a total of 12 FFPE tissue specimens (3
each from MF, LyP, SPTL, and LRP) were selected based on
their IDO1 expression status to cover both strongly positive and
negative cases. Double IHC for CD163 (cat#NCL¡L-CD163,
mouse, 1:100, Novocastra) and IDO1 (cat#04–1056, rabbit,
1:2000, Merck Millipore) was performed using Vectastain ABC-
AP Kit (cat#AK-5002, mouse, Vector Laboratories)/Permanent
AP-Red Kit (cat#BCB-20041, Nordic BioSite) and Vectastain
Elite ABC HRP Kit (cat#PK-6101, rabbit, Vector Laboratories)/
Permanent HRP Green Kit (cat#KDB-10049, Nordic BioSite),
respectively.
Double IHC staining for CD30 (cat#ab132080, 1:1000, rab-
bit, Abcam) and IDO1 (cat#MAB5412, 1:50, mouse IgG3,
Chemicon International) was performed using Vectastain Elite
ABC HRP Kit /Permanent HRP Green Kit and Vectastain
ABC-AP Kit /Permanent AP-Red Kit, respectively. Primary
antibodies were replaced with 1% BSA/PBS in negative con-
trols. Microscopes from Leica Biosystems were used.
Double immunoﬂuorescence
Double immunoﬂuorescence (IF) for CD33 (cat#133M-17,
mouse IgG2b, 1:200, Cell Marque) and IDO1 (cat# mouse
IgG3, 1:200, clone MAB5412, Chemicon International) were
performed on the same sample set as analyzed by double IHC
(see above). AlexaFluor-594 anti-mouse IgG2b antibody
(cat#A-21145, 1:1000, Thermo Scientiﬁc) and AlexaFluor-488
anti-mouse IgG3 antibody (cat#115–545–209, 1:1000, Jackson
ImmunoResearch Laboratories) were used as secondary anti-
bodies and the slides were analyzed and photographed using an
Axio Imager.Z2 upright epiﬂuorescence microscope (Carl Zeiss
AG, Oberkochen, Germany) and checked with a Zeiss Axio
Imager.Z1 upright epiﬂuorescence microscope equipped with a
Zeiss ApoTome for structured illumination.
Cell lines
Cells were suspended in 10% DMSO–fetal bovine serum (FBS)
and stored in liquid nitrogen using standard procedures. The
MF-derived cell line MyLa200025 was grown in DMEM Gluta-
max (cat# 10566–016, Gibco/Invitrogen), supplemented with
10% FBS (cat# SH30071.01, HyClone, GE Healthcare Bio-Scien-
ces,) and penicillin–streptomycin (100 U/mL) for a maximum of
20 passages. The Mac1 cell line had been established from
peripheral blood cerebriform lymphocytes of a 31-year-old male
patient with indolent LyP, while Mac2A was established from a
skin tumor of the same patient after progression to ALCL. Albeit
clonally related, Mac1 and Mac2A are genomically and tran-
scriptionally distinct.27 Mac1, Mac2A, and HeLa cell lines were
grown in RPMI 1640 (cat# 31870–082, Gibco/Invitrogen), sup-
plemented with 2 mM glutamine, 10% FBS, and penicillin–strep-
tomycin (100 U/mL). The cell lines have been authenticated at
the DSMZ (Braunschweig, Germany) using short tandem repeat
DNA typing. For all subsequent experiments, fresh aliquots were
thawed, and only cells cultured for less than 20 passages in 8%
CO2 were used. Cell yield and viability were followed using (1:2)
0.4% Trypan Blue or the Dojindo Cell Counting Kit-8 (Dojindo
Laboratories) according to the manufacturer’s instructions.
Western blot
MyLa2000, Mac-1, and Mac-2A cell lines were washed twice
with ice cold PBS. Cell pellets were resuspended in RIPA buffer
(50 mM Tris–HCl pH 7.2, 150 mM NaCl, 2 mM EDTA, 1%
NP-40, 0.1% SDS) with EDTA free protease inhibitor
(cat#04693132001, Roche) and incubated on ice for 30 min.
Cell lysates were centrifuged at 12.000xg at 4C for 20 min.
Protein concentration was determined using the Pierce BCA
Protein Assay Kit (cat#23225 Thermo Scientiﬁc). 34 mg and
25 mg of protein were used for TDO and IDO western blot
analysis, respectively. Samples were boiled at 70C for 10 min
with Laemmli Sample Buffer (cat#161–0747, Bio-Rad). Protein
lysates were separated by 10% SDS-PAGE electrophoresis,
transferred onto nitrocellulose membrane (cat#NBX
085C001EA, Millipore) 100 V for 90 min. Membranes were
incubated with anti-TDO2 (cat#LS-B5791, 3:1000, Life Span
Biosciences), anti-IDO1 (cat#MAB5412, 1:500, Millipore) anti-
bodies overnight at 4C, and with anti b-actin (cat#4970L,
Table 1. Serum KYN/Trp ratios in relation to MF disease stage.
Case1 Stage KYN/Trp (nM/mM) KYN (nM) Trp (mM)
n D 10 Healthy controls 30 § 2 2241 § 109 75 § 4
20 IVA2 180 4490 25
10 NA 115 6120 53
1 IVA 110 5590 51
18 III2 59 4170 70
16 IVA 58 3290 57
26 IIA2 53 3650 69
2 IIB- 48 3350 69
8 IA 47 1940 42
19 IA 44 2330 53
7 IVA2 42 2830 67
23 IIB 38 3080 82
14 IA_ 38 2520 67
9 IA 37 2450 66
13 IA_ 36 2390 66
5 IB_ 34 1760 52
15 IIIB 34 2190 65
3 IB_ 34 2000 59
21 IIA 33 1380 42
11 IA 33 2640 79
6 IIA 28 1830 66
22 IA 27 2490 91
24 IA 25 1780 71
17 IB 25 2230 89
12 IA 25 1470 58
4 IA 25 1550 62
25 IVA2 20 1120 57
1MF patient sera (n D 26, non-fasting) and healthy controls (n D 10, non-fasting).
2Deceased during follow-up. There was no correlation between the serum KYN/Trp
ratio and second malignancies in any patient category. NA D not applicable, diag-
nosed later MF/AITL, angioimmunoblastic T-cell lymphoma (mean C/¡SE).
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1:1000, Cell Signaling) for 1 h at RT. After washing, the mem-
branes were incubated with anti-rabbit HRP-conjugated
secondary antibody (cat#PO448, Dako) or with anti-mouse
HRP-conjugated secondary antibody (cat#AP308P, Millipore).
Proteins were detected using the Clarity ECL reagent (cat#170–
5061, BioRad). TDO2 and IDO1 expression values were
normalized against b-actin using the ChemiDoc MP Imaging
System and adjusted density values were calculated using the
Image Lab software (Bio-Rad).
L-Kynurenine concentrations in CTCL-derived cell lines
The KYN concentrations of cell culture supernatants were mea-
sured by L-Kynurenine ELISA kit (cat#BA-E-2200, ImmuSmol)
according to the manufacturer’s instructions. The OD values
were measured on a Multiscan FC spectrophotometer (Thermo
Scientiﬁc) and results were analyzed using non-linear regression.
Determination of Trp metabolites in patient sera
Sera were stored at –80C until analyzed by liquid chromatogra-
phy–electrospray ionization–tandem mass spectrometry (LC–
ESI–MS/MS) as described previously32 to determine the concen-
trations (mM) of QA, 3-hydroxykynurenine (3-HK), NAm,
kynurenine (KYN), tryptophan (Trp), xanthurenic acid (XA),
kynurenic acid (KA), anthranilic acid (AA), 3-hydroxyanthra-
nilic acid (3-HAA), 5-hydroxy-indole-3-acetic acid (HIAA),
indole-3-lactic acid (ILA), and indole-3-acetic acid (IAA).
Statistical analysis
IMB SPSS Statistics 22 software was used to calculate the statis-
tical signiﬁcance between variables using either the Kruskal–
Wallis test or the Mann–Whitney U test.
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